Cleared Traditional

GLOBIN-TERGE (K780817) - FDA 510(k) Clearance

K780817 · Simmler & Son, Inc. · Hematology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Jul 1978
Decision
70d
Days
-
Risk

K780817 is an FDA 510(k) clearance for the GLOBIN-TERGE.

Submitted by Simmler & Son, Inc. (Mchenry, US). The FDA issued a Cleared decision on July 27, 1978 after a review of 70 days - a notably fast clearance cycle.

This device falls under the Hematology FDA review panel. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Simmler & Son, Inc. devices

Submission Details

510(k) Number K780817 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received May 18, 1978
Decision Date July 27, 1978
Days to Decision 70 days
Submission Type Traditional
Review Panel Hematology (HE)
Summary -
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
43d faster than avg
Panel avg: 113d · This submission: 70d
Pathway characteristics
Predicate-based equivalence.

Device Classification

Product Code -
Device Class -